No Data
No Data
Intellia Therapeutics | 10-Q: Quarterly report
Intellia Hereditary Angioedema Candidate Meets Phase 2 Primary Endpoint
Buy Rating Affirmed for Intellia Therapeutics on Strong Clinical Progress and Positive KOL Feedback
Express News | Intellia Therapeutics Q2 2024 GAAP EPS $(1.52) Misses $(1.24) Estimate, Sales $6.957M Miss $19.162M Estimate
Express News | Intellia Therapeutics Inc: Ended Q2 With About $940 Mln in Cash
Intellia Therapeutics GAAP EPS of -$1.52 Misses by $0.29, Revenue of $6.96M Misses by $11.29M
No Data
10baggerbamm : why is anybody even bothering with this woman she's been negative year-to-date she is no conviction she gives price targets pie in the sky and if she really believed in them she would not be selling these companies she's full of shit she made money one year one time everything else has been a disaster
tankeng : yes this woman has problems and arrogant
OhNowGombie : Another quack you mean? Totally out of her gourd too